Henagliflozin on Myocardial Fibrosis in Obese Patients (LY2026-317-C)
Effect of Henagliflozin on Myocardial Fibrosis in Obese Patients: A Prospective, Randomized, Controlled Study.
This study evaluates the anti-fibrotic efficacy and safety of henagliflozin versus metformin in non-diabetic obese patients with subclinical myocardial fibrosis, explores whether the benefit is mediated by metabolic improvement or direct myocardial protection, and aims to provide high-level evidence for early pharmacological intervention.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This study will be based on an established specialized cohort of non-diabetic patients with simple obesity and a multi-omics database. By integrating clinical data with multidimensional information including genomics, metabolomics, and proteomics, patients at high risk of myocardial fibrosis will be identified. After myocardial fibrotic changes are further confirmed by CMR, eligible participants will be randomly assigned to the control group (metformin) or the intervention group (henagliflozin). The treatment period will be 24 weeks, followed by a 24-week safety follow-up period. The difference in the change in the degree of myocardial fibrosis before and after treatment between the two groups will be compared to determine the efficacy of henagliflozin in counteracting myocardial fibrosis in the non-diabetic obese population. This project aims to provide high-level evidence-based medical evidence for targeted pharmacological intervention of obesity-related early cardiac damage, with the goal of improving the long-term prognosis of this population.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Jing Ma
- Phone Number: 021-68383420
- Email: majing3436@163.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- BMI ≥ 28 kg/m², or waist circumference ≥ 90 cm in men or ≥ 85 cm in women, or body fat percentage ≥ 25% in men or ≥ 30% in women;
- Adults aged 18 to 65 years;
- ECV greater than 30%;
- No participation in other clinical trials within the past three months.
Exclusion Criteria:
- Diagnosed with diabetes mellitus or prediabetes;
- History of coronary artery disease (coronary stenosis > 50% on coronary angiography or coronary computed tomography), history of myocardial infarction, history of coronary artery bypass grafting or percutaneous coronary intervention; non-ischemic cardiovascular diseases such as idiopathic cardiomyopathy, valvular disease, congenital heart disease, or cor pulmonale; arrhythmia or bundle branch block on electrocardiogram; implantation of a cardiac pacemaker or defibrillator;
- Uncontrolled hypertension: systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg during the screening visit (mean of three blood pressure measurements in the supine position);
- Symptomatic hypotension and/or systolic blood pressure < 90 mmHg at V1 or V2, or patients judged by the clinician to have hypovolemia;
- Use within 3 months of: 1) medications that may affect body weight or glucose metabolism, including systemic glucocorticoids (excluding topical, ophthalmic, nasal spray, or inhaled preparations; excluding low-dose or overnight dexamethasone suppression test use), growth hormone, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic/tetracyclic antipsychotic drugs, other psychiatric medications or sedatives (e.g., imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid, valproic acid derivatives, lithium salts), etc.; 2) traditional Chinese medicines, Chinese patent medicines, herbal medicines, health supplements, meal replacements, etc., with weight-loss or glucose-lowering effects; 3) use of or current use of the following weight-loss drugs or drugs containing the following ingredients, such as: sibutramine hydrochloride, orlistat, phentermine, phenylpropanolamine, clobenzorex, fenfluramine, amfepramone, lorcaserin, phentermine/topiramate combination, naltrexone/bupropion combination, etc.; 4) use of glucose-lowering drugs, such as metformin, α-glucosidase inhibitors, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, thiazolidinediones (TZDs), insulin, etc.;
- Other endocrine and metabolic diseases such as hyperthyroidism, hypothyroidism, acromegaly, diabetes insipidus, or Cushing's syndrome;
- Concurrent malignant tumors;
- Severe liver disease (Child-Pugh class C) or liver enzymes (ALT/AST) > 3 times the upper limit of normal;
- Estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m²;
- Cognitive impairment, or concomitant infectious or autoimmune diseases;
- History of recurrent urinary or reproductive tract infections;
- Patients who refuse henagliflozin or metformin treatment, or who are allergic to henagliflozin, metformin, or their excipients; those with incomplete questionnaires or incomplete data;
- Pregnant or breastfeeding women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intervention Group
|
Oral henagliflozin 10 mg once daily for 24 weeks, administered at a fixed dose without adjustment. Used in non-diabetic obese patients with subclinical myocardial fibrosis as an off-label investigational treatment. |
|
Active Comparator: Control Group
oral metformin tablets 2000 mg/day; or the maximum tolerated dose (≥1000 mg/day). |
Oral metformin titrated to 2000 mg/day (1000 mg twice daily), or the maximum tolerated dose (≥1000 mg/day), for 24 weeks. Dose titration: 500 mg twice daily for weeks 1-2, then 1000 mg twice daily from week 3 if tolerated. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline in Myocardial Extracellular Volume (ECV) Fraction at 24 Weeks
Time Frame: Baseline to Week 24
|
Change from baseline in myocardial extracellular volume (ECV) fraction, as measured by cardiac magnetic resonance (CMR) T1 mapping pre- and post-contrast. ECV is calculated from pre- and post-contrast T1 relaxation times and the patient's hematocrit. The between-group difference in ΔECV (Henagliflozin vs. Metformin) will be compared; continuous data will be summarized as mean ± SD and analyzed using mixed-effects models. |
Baseline to Week 24
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change from Baseline in Epicardial Adipose Tissue (EAT) Volume at 24 Weeks
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Left Ventricular Ejection Fraction (LVEF) at 24 Weeks
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Cardiac Output at 24 Weeks
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Heart Rate at 24 Weeks
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Peak Filling Rate at 24 Weeks
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Stroke Volume Index (BSA-corrected) at 24 Weeks
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in End-Systolic Volume Index (BSA-corrected) at 24 Weeks
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in End-Diastolic Volume Index (BSA-corrected) at 24 Weeks
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Left Ventricular Mass Index (BSA-corrected) at 24 Weeks
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Early-to-Late Filling Ratio (E/A) at 24 Weeks
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in LV Mass to End-Diastolic Volume Ratio (MVR) at 24 Weeks
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Cardiac Index at 24 Weeks
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Body Weight at 24 Weeks
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Body Mass Index (BMI) at 24 Weeks
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Systolic Blood Pressure at 24 Weeks
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Diastolic Blood Pressure at 24 Weeks
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Glycated Hemoglobin (HbA1c) at 24 Weeks
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Fasting Plasma Glucose at 24 Weeks
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in HOMA-IR (Insulin Resistance Index) at 24 Weeks
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Total Cholesterol at 24 Weeks
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at 24 Weeks
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at 24 Weeks
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Triglycerides at 24 Weeks
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in High-sensitivity CRP (hsCRP) at 24 Weeks
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Time Frame: Up to 48 Weeks
|
Up to 48 Weeks
|
|
Number of Participants With Genitourinary Tract Infections
Time Frame: Up to 48 Weeks
|
Up to 48 Weeks
|
|
Number of Participants With Gastrointestinal Adverse Events
Time Frame: Up to 48 Weeks
|
Up to 48 Weeks
|
|
Number of Participants With Ketoacidosis
Time Frame: Up to 48 Weeks
|
Up to 48 Weeks
|
|
Number of Participants With Serious Adverse Events (SAEs)
Time Frame: Up to 48 Weeks
|
Up to 48 Weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jing Ma, Department of Endocrinology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- LY2026-317-C
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.